The treatment of patients with endoprosthetic failure presents a challenge due to resultant insufficient bone stock, poor muscle function, and lack of normal soft tissue coverage. A prior study by Kabo et al documented a 7-year survival of 66% for revision endoprostheses, reflecting the difficulty of creating a durable construct in a revision setting. 5 In particular, the revision of cemented endoprostheses is technically demanding. The removal of the implant from stress shielded bone is often fraught with challenges and the ease of simply "cutting above" the cement mantle is tempting for surgeons. This, however, uses additional bone stock and dramatically limits the number of revisions a patient can undergo in their lifetime. It also raises the level of amputation if a complication arises for which limb salvage is no longer an option. More conservative revision techniques have been described including converting to a short compression fixation device (ZimmerBiomet Compress), custom cross-pin fixation, telescoping method, and using a cement-in-cement revision technique. [7] [8] [9] [10] [11] [12] [13] While
Compress and custom cross pin fixation have shown encouraging results as a revision technique, data were all from small series and the implants often require FDA and IRB approval, delaying the surgery many weeks. The CiC revision technique is thus an appealing option as it does not utilize additional bone stock and uses off-the-shelf implants.
Given the limited options available for cemented endoprosthetic revision and the potential of the CiC revision technique as a conservative and repeatable procedure, we sought to answer several questions. Primarily, we endeavored to understand the long-term survival of and complications from the cement in cement (CiC) revision technique and subsequent revisions. Additionally, we investigated the influence of failure mode and anatomic location on prosthesis survival.
| METHODS
This is a retrospective review of our endoprosthesis database consisting of 512 consecutive cemented endoprosthetic reconstructions performed for oncologic diagnoses between 1980 and 2014.
Research approval was granted by the Institutional Review Board. All primary endoprostheses were implanted by the senior author (JJE) at a single institution. Revisions were performed by the senior and lead authors (JJE and NMB). Follow-up was performed at a single institution and data were prospectively entered into a single database.
Patients were identified for inclusion in the study if they were revised at the cement-implant interface using a CiC revision technique.
Patients were excluded if the revision surgery included bushing changes, revisions for adjacent joint pathology, revisions into native bone or adjacent joints (total femur endoprostheses), and planned expansions of growing implants. Patients with upper extremity implants were excluded as the rotational stress placed on the cement is dramatically less than that for lower extremity patients. Patients with endoprostheses originally placed for non-oncologic diagnoses were excluded as they often had undergone multiple operations by outside physicians before endoprosthetic reconstruction. Patients all had chemotherapy and/or radiation as per protocol for their underlying diagnosis at the time of their original endoprosthesis placement. No patient was actively receiving chemotherapy or radiation at the time of the CiC revision.
Of the 512 patients who underwent cemented endoprosthetic reconstruction of the lower extremity for oncologic disease, 54 (10.5%) underwent a CiC revision (mean age 32 years, range 13-81).
Mean follow up from CiC revision was 127 months (range 6-326 months).
| Surgical technique
All primary endoprosthetic reconstructions were performed by the senior author (JJE) and revisions were performed by either the lead or senior author (NMB or JJE). Our surgical technique for primary implantation has been reported in full previously. 6, 14 Primary tumor resections were in accordance with widely accepted oncologic principles. [14] [15] [16] [17] All primary reconstructions were implanted with antibiotic-impregnated cement (Stryker Simplex P with Tobramycin, Mahwah, NJ) using modern generation cement technique.
The cement-in-cement revision technique was used for all patients during the study for whom (i) the cemented stem of the endoprostheses was noted to be loose or fractured; (ii) the remaining bone stock retained a cylinder of bone of at least 127 mm in length At each follow-up visit, patients were assessed by the revised Musculoskeletal Tumor Society functional evaluation (MSTS). 18, 19 For this system with a range of 0-30 points, the functional assessment is based on the analysis of subjective factors (pain, functional activities, and emotional acceptance), and factors specific to the upper extremity (positioning of the hand, manual dexterity, and lifting ability) or the lower extremity (use of external supports, walking ability, and gait). The 
| Demographics
The 54 patients who underwent CiC revision and were included in the study had a mean age of 32 at time of index CiC surgery (range 13-81). 
| Complications
Five of 54 (9%) initial CiC revisions failed due to infection. Overall complications from each revision stage are presented in Table 1 .
Subsequent complications based on initial failure mode are presented in Figure 3 . An additional 4 of 31 (13%) subsequent CiC revisions became infected. The limb salvage rate was 87% (47/54) in this cohort.
| Failure mode
Of the 29 cases of CiC revision performed for aseptic loosening, nine (31%) were subsequently revised for aseptic loosening and six (29%) for structural failure. Of the 20 cases of CiC revision performed for 
| Anatomic location
In the initial revision cohort of 54 patients, there was a difference in the failure rate between anatomic location. 5-, 10-, and 15-year survival rates for DFR prostheses (n = 41) was 75.5%, 49.2%, and 29.6%, respectively. A total of 5-, 10-, and 15-year survival rates for PFR prostheses (n = 6) was 83.3%, 62.5%, and 62.5%, respectively. A total of 5-and 10-year survival rates for PTR prostheses (n = 6) was 66.6% and 22.2%, respectively ( Figure 4 ).
| DISCUSSION
The evaluation of techniques that are able to address the problem of cemented endoprosthetic revision are increasingly important as oncologic patient survival continues to improve. A CiC revision technique in this context was thought to demonstrate promise due to the fact that it is a conservative procedure that requires little to no additional bone resection, can be repeated multiple times before a higher-level reconstruction is required, and is performed with off-the shelf implants available at any time ( Figure 5 ).
However, long-term outcomes of this procedure were previously unknown. In this study, 15-year survival of CiC revision reconstruction was 34.4% and 15-year survival of a subsequent CiC revision was 39.1%, with an overall limb salvage rate of 87%. Of the seven amputations performed, all were for tumor progression (n = 2) or infection (n = 5).
Survival rates differed by anatomic location, but were similar across different modes of failure. Subsequent revision failures were more likely to fail by the same mechanism as the initial failure, and were also more likely to become infected.
| Survival
Initial and subsequent CiC revision cohorts demonstrated similar implant survival rates, and both were significantly lower than the survival rates for primary endoprosthetic reconstructions published by our group and others. 1, 3, 4, 6, 21 This is not unexpected given the (i) challenges of revision arthroplasty surgery in general and (ii) the attempted conservative nature of this operation avoiding native, healthy bone. However, the fact that survival of subsequent revisions was equal to that of the initial CiC revision provides optimism in the reproducibility and durability of this technique. Nonetheless, there is no question this is a salvage technique and should be performed with tempered expectations.
FIGURE 3
Among initial failure modes of (A) aseptic loosening and (B) structural failure, frequencies of subsequent modes of failure including aseptic loosening, structural failure, infection, and tumor progression FIGURE 4 Kaplan-Meier curves that represent survival of CiC revisions based on location including distal femur, proximal femur, and proximal tibia. Aggregate survival of all three locations described are represented by "Initial Revision"
When compared specifically to total femoral replacements, an alternative for a failed cemented endoprosthesis, the CiC implant survival is far more appealing. Recent literature on TFR survival demonstrates a 5-year revision-free survival of 48%, to which our 15-year data were comparable. 12 With MSTS functional scores of 24 with TFR, 22 the CiC technique appears to have superior implant survivorship and functional results. In addition, a recent study by Zimel et al looking at compressive osseointegration fixation for DFR revision showed a 10-year implant survival rate of 74%, with a mean MSTS score for those patients who had retained their implant of 27. 23 While this series compares favorably to our results and presents an attractive option in some revision scenarios, applicability is limited due to logistic requirements. Unless the primary implant was made by the same manufacturer as the compression osseointegration implant, this revision technique necessitates Institutional Review Board and FDA approval for a custom implant, rendering it unavailable to the surgeon who requires it on a semi-urgent basis. Conversely, the CiC technique is an available off the shelf revision option regardless of manufacturer.
| Complications
Based on previously published data, primary infection rate after cemented endoprosthetic reconstruction in our overall cohort of 512 patients was 2%. 21 We saw an increase in the incidence of infection at each revision intervention stage: CiC revisions failed from infection 9% of the time, subsequent revisions 13%, and tertiary revisions 55% (6/11 patients). These infection rates are comparable to published index procedure infection rates, which range greatly from 3% to 34%. 1, 3, 9, 24 Of note, our demonstrated increase in infection may be influenced by technological advances and increasing sensitivity of assays to determine infection, resulting in the identification of indolent infection cases that previously would have been declared aseptic.
However, the conclusion that subsequent endoprosthesis surgery is more likely to lead to an infection is critical. We believe this conclusion highlights the appeal of the CiC revisions, as other revision strategies that use more proximal bone could jeopardize a functional amputation if the infection cannot be cleared. Other, noninfectious complication rates from the CiC technique are in line with previously published endoprostheses series, with aseptic loosening (54%) and structural failure (37%) as the most common cause for failure. 9, 10 Forty-seven of 54 (87%) patients achieved successful limb salvage using the CiC technique. We have previously shown a limb salvage rate of 81% following index procedure in this cohort, 15 and published rates from index endoprosthesis reconstruction range from 70% to 92%. 1, 3, 4 In our series, all amputations were performed for tumor recurrence or infection, in accordance with previous datasets, demonstrating the difficulty in saving the limb in these settings. 4 In our previously published cohort of 512 patients, 40% of infected prostheses and 89% of local recurrences resulted in an amputation. 5 Finally, our patients demonstrated a revised MSTS score of 27, which agrees with previous reports from our group that 64/64 patients evaluated for functional status at 13.2 years continued to be active and functional in their homes. 22 Similar studies have shown a revised MSTS score of 27 after revision DFR at 10 years follow-up. 23 
| Failure mode
In our cohort, we saw a correlation between initial failure mechanism and subsequent failure mechanism. When a patient failed for aseptic loosening or structural failure, they were more than 50% likely to fail by the same mechanism when they failed again. These findings stress the importance of life-long follow-up for these patients, enabling us to identify patients at risk of failure before their complication progresses to catastrophic status.
| Anatomic location
We saw a correlation between anatomic location of CiC revision and survival rate. In our cohort, PFR's showed highest survival rate, followed by DFR then PTR. Of note, numbers of patients were small in PFR and PTR groups (n = 6), so the reader should interpret these findings accordingly. However, these findings agree with other authors, who have demonstrated that tibia prostheses required the highest revision rate of any anatomic location, (46%) and higher than DFR (10%). 1 Finally, the Henderson series demonstrated worse overall survival in the combined DFR-PTR and PTR groups at 15-30 years, which is in concordance with our findings of a decreased survival rate for PTR. 9 We find that our PTR patients have more challenging soft tissue environments, especially in the revision setting, which provides a rationale for these findings.
| Limitations
This study has a number of limitations, including its retrospective design and lack of a control group. Both of these limitations are difficult to overcome considering first the rarity of musculoskeletal tumors, and the smaller number of those that required a revision after endoprosthetic reconstruction. We are able to compare our results to historical controls as a frame of reference, but no direct comparison with another reconstruction technique can be made. The limited power of the study is further diminished when we stratify by anatomic location.
Nonetheless, we believe the trend toward better survival for PFR > DFR > PTR CiC is worth noting, especially as it mirrors existing trends in primary reconstructions. 21 
| CONCLUSIONS
At long-term follow up, endoprostheses revised with the CiC technique showed consistent 15-year survival from initial (34%) to subsequent (39%) revision. We showed that the CiC technique is a repeatable, conservative procedure in these challenging patients.
While we expect a significant complication rate from this procedure, including an increasing risk of infection, we also expect to be able to repeat these surgeries for the life of the patient with a reasonable chance of maintaining a well-functioning limb.
In considering cemented endoprostheses and the CiC revision 
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